奥赛康(002755.SZ)：子公司与阿诺医药达成许可引进协议

Group 1 - The core viewpoint of the news is that Aosaikang (002755.SZ) has entered into a licensing agreement with Hangzhou Anuo Biopharmaceutical Technology Co., Ltd. for the innovative drug project AN9025, which provides Aosaikang exclusive rights for development, production, and commercialization in the licensed area [1] - Aosaikang will pay a non-refundable upfront fee of 35 million RMB within 10 working days after the agreement takes effect, along with milestone payments related to product development, registration, and market launch, totaling up to 470 million RMB [1] - The AN9025 project is a novel oral pan-RAS inhibitor designed to treat RAS mutation-driven solid tumors, having received clinical trial approval from the FDA in the United States [1] Group 2 - Aosaikang is building a robust and promising R&D pipeline in the oncology treatment field through independent research and strategic partnerships [2] - The introduction of the AN9025 project, a pan-RAS inhibitor, is expected to enhance the company's positioning in the treatment of lung cancer, colorectal cancer, and pancreatic cancer, creating synergistic effects with existing clinical and commercialization resources [2] - The addition of AN9025 will enrich the company's innovative drug pipeline and strengthen its competitiveness in the anti-tumor treatment sector, positively impacting the company's strategic layout [2]